AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
Trial ID or NCT#
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with multiple system atrophy.
Contact us to find out if this trial is right for you.
About this Clinical Trial
A 12 week Multicenter Randomized Parallel Group Study to Assess the Safety, Tolerability, Pharmocokinetics Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography of AZD3241 in Subjects with Multiple System Atrophy
Your Message Will Go ToMaria Coburn
Go Back To The Trial